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Appreciation

An appreciation of Ralph Marvin Steinman (1943–2011)
Ralph Steinman, an editor at the
Journal of Experimental Medicine
since 1978, shared the 2011 Nobel
Prize in Physiology or Medicine for his
discovery of dendritic cells (DCs) and
their role in immunity. Ralph never
knew. He died of pancreatic cancer
on September 30, 3 days before the
Nobel announcement. Unaware of his
death at the time of their announcement, the Nobel Committee made the
unprecedented decision that his award
would stand. Ralph was the consummate physician-scientist to the end.
After his diagnosis, he actively participated in his 4.5 years of treatments,
creating experimental therapies using
his own DCs in conjunction with the
therapies devised by his physicians,
all the while traveling, lecturing, and
most of all pursuing new investigations in his laboratory. For 38 years—
from his discovery of DCs to his Nobel
Prize—Ralph pioneered the criteria and
methods used to identify, isolate, grow,
and study DCs. He and his colleagues
demonstrated that DCs are initiators
of immunity and regulators of tolerance. In his most recent studies, Ralph
was harnessing the specialized features of DCs to design improved vaccines. The following synopsis describes
some of his seminal discoveries.

Until Ralph Steinman discovered DCs,
the innate and adaptive systems had been
considered separate entities for nearly a
century. Innate immunity involved Elie
Metchnikoff’s phagocytes, particularly
macrophages that internalize and kill
microbes. Paul Ehrlich’s adaptive immunity involved lymphocytes that produce
the antibodies that are so often used
for clinical benefit. A new dimension to
Ehrlich’s work was first described in the
1940s by Merrill Chase, a researcher at
the Rockefeller Institute who showed
that lymphocytes, rather than antibodies,
bring about adaptive immunity. It is
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now known that this cell-mediated
immunity involves T lymphocytes in
many different helper, cytotoxic, and
suppressor forms, and that they are all
controlled by DCs. Ralph’s discovery
thus provided the missing link between
innate and adaptive immunity. DCs are
essential for understanding how the immune system works during health and
how diseases develop. They are unavoidable targets for identifying new
preventions and therapies.
Discovery

During his medical training, Ralph was
challenged to learn how an antigen
provokes an immune response. He recognized that MacFarlane Burnet’s clonal
selection theory could not account for
how the body responds to substances—
both foreign and self—by generating a
diverse repertoire of immune cells, each
with a single, distinct antibody as its
receptor (Burnet, 1957). Because clonal
selection could not be initiated by adding foreign proteins to lymphocytes,
it was thought that mysterious “accessory” cells were also required to induce
immunity. One idea was that accessory
cells were macrophages.
The story of DCs began in 1970,
when Ralph joined the Rockefeller

University as a postdoctoral fellow in
the laboratory of Zanvil (Zan) Cohn,
the founder of modern macrophage
biology. This was an ideal place to directly test whether macrophages would
trap intact antigens and present them to
lymphocytes. The laboratory was founded
by the premier microbiologist René
Dubos, who recognized the need to study
the host during infection. He had been
the ideal mentor for James Hirsch and
Zan, two physicians devoted to infectious disease, who pursued elegant careers
with phagocytes. Dubos, Hirsch, and
Cohn were all editors of this journal.
Ralph’s initial research focused on
endocytosis of proteins in macrophages.
But when he was unable to find reservoirs of intact antigen on peritoneal
macrophages, he turned to the spleen to
see if this organ might harbor cells responsible for generating immunity
(Steinman and Cohn, 1972).
Ralph and Zan discovered DCs in
1973. Looking through a phase contrast
microscope, they encountered a population of cells from the spleen that had
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never been seen before and did not
look like macrophages. The cells were
elongated with unusual stellate, or treelike, processes that were constantly
forming and retracting. Ralph named
them dendritic cells (from the Greek
word dendreon for tree; Steinman and
Cohn, 1973, 1974).
Purification

Mixed leukocyte reaction

Functional studies on DCs began once
Ralph had pure DC populations. He
noted that DCs expressed high levels of
MHC proteins. Therefore, along with
2338

Antigen presentation

The next few years were very productive, and DCs were quickly shown to
effectively present antigens to T cells.
Michel Nussenzweig, the first student
to work on DCs, showed that DCs capture antigens and present them to cytolytic T lymphocytes. Michel modified
syngeneic thymocytes with trinitrophenyl and showed that DCs could capture, process, and present the antigen
to produce MHC-restricted cytolytic
T lymphocytes (Nussenzweig et al.,
1980). Michel also developed 33D1, the
first DC-specific monoclonal antibody
(Nussenzweig et al., 1982). Although
20 years passed before the antigen recognized by 33D1 was characterized at
the molecular level (Dudziak et al.,
2007), 33D1 was important because it
revealed the first molecular distinction

between DCs and all other immune cell
types. Michel and Ralph used this
monoclonal antibody to selectively deplete DCs, but not monocytes, from
spleen suspensions to show that the DC
was the primary stimulator of the MLR
in bulk spleen (Steinman et al., 1983).
Another student, Wes van Voorhis,
identified DCs in human blood
(Van Voorhis et al., 1982) and developed a monoclonal antibody that killed
monocytes, but not DCs. These experiments were important because they provided evidence that DCs also existed in
humans and set the stage for later immu
nization experiments (Inaba et al., 1983).
Ralph and Kayo Inaba demonstrated a role for DCs in stimulating
naive B cells to produce antibodies capable of binding sheep red blood cells
and protein antigens. They showed that
once helper T cells had been activated
by DCs, the T cells could interact efficiently with antigen-presenting B cells
to drive B cell clonal expansion and anti
body production (Inaba and Steinman,
1984, 1985; Inaba et al., 1984). They
noted that antigen-reactive T cells clustered on the surfaces of the very small
number of DCs, typically 1% or less of
the total cells, in their experimental systems. Analyzing these T cell–DC clusters, they showed that DCs provide the
“microenvironment” for T cell activation and generation of cellular immunity (Inaba et al., 1987).
In all of these systems, small numbers of DCs would elicit a T cell response, whereas much larger numbers
of other cell types failed to do so. These
experiments led to the realization that
there are two stages to every immune
response. The first is an afferent stage
during which DCs stimulate the growth
and differentiation of rare quiescent
precursors of antigen-specific helper
and cytolytic T cells. The second stage
is an efferent limb during which T cells
that have been activated by DCs divide
in response to encounter with antigens
that have been processed and presented
by other cells, including B cells and
macrophages. This second stage yields
large numbers of effector T cells that
participate in many immunological reactions (Steinman and Nussenzweig,
An appreciation of Ralph Marvin Steinman | Moberg
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It took nearly 5 years to get pure populations of DCs and to compare their
functions with those of other cell types.
DCs were rare (<1% of mouse spleen
cells), and their only unique markers
were their unusual shape and movement. Fortunately, George Palade, Phil
Siekevitz, David Sabatini, Günter
Blobel, and Christian de Duve—who
were in the process of inventing
modern cell biology—were neighbors
of the Cohn laboratory in Rockefeller’s
Bronk Building. The de Duve laboratory’s expertise in density gradient centrifugation for subcellular fractionation
was key to Ralph’s purification methods. The elegant and ingenious steps
Ralph worked out started with centrifuging spleen cells on a bovine serum
albumin gradient, on which semipurified DCs rose to the top. He then placed
this fraction on glass for one hour, delicately washed away all but the DCs and
some macrophages, and cultured these
cells overnight to let the DCs detach
from the culture dish and float into suspension.The lingering few macrophages
were removed by adding antibodycoated sheep red blood cells and centrifuging them out (Steinman et al., 1979).
This procedure was laborious, and the
DC yield was poor. As a result, few
laboratories attempted to reproduce it
or to work with DCs for many years.
After an antibody was developed to
CD11c, an antigen expressed by DCs,
activated monocytes, and NK cells,
purification became routine (Metlay
et al., 1990).

Maggi Witmer-Pack, he evaluated their
capacity to stimulate the mixed leukocyte reaction (MLR). This T cell reaction had been used for 15 years to detect
differences in MHC antigens between
potential donors and recipients of organ
transplants. At the time, it was termed
mixed lymphocyte reaction because it
was thought that B cells from the potential transplant donor triggered the
division of T cells of the potential transplant recipient. Ralph showed that the
newly identified DCs were 100 times
more potent than bulk spleen cells at
inciting the MLR, and that antigenbearing B cells and macrophages contributed little to initiating the reaction.
The DCs were converting transplantation antigens into “immunogens” capable of eliciting cell and organ rejection.
In 1978, Ralph predicted that DCs
would “prove to be a critical accessory
cell required in the generation of many
immune responses” (Steinman and
Witmer, 1978). However, this interpretation was not accepted by most
immunologists because of the unusual
features of the MLR in comparison to
other immune responses. For example,
the antigens responsible for initiating
the MLR were not well defined, and
vigorous in vitro responses apparently
required no priming.

Appreciation

1980; Steinman, 1991). Together, these
afferent and efferent limbs solve the
conundrum of how rare antigenspecific lymphocytes are selected and
mobilized to bring about vigorous specific responses.
Maturation

Growing DCs

Early research on DCs was limited by
the need to isolate these scarce cells
from primary tissues. During the early
1990s, Ralph and colleagues identified
methods for stimulating bone marrow
cells to grow and differentiate in vitro
into cells that displayed many of the
phenotypic characteristics of DCs
(Inaba et al., 1992a,b, 1993a; Romani
et al., 1994). By 2000, other investigators
JEM Vol. 208, No. 12
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To gain information about DCs in nonlymphoid tissues, Ralph turned to the
epidermal Langerhans cells, which were
also known to express high levels of
MHC class II proteins. With Gerold
Schuler, Niki Romani, and Kayo,
Ralph found that Langerhans cells
needed to differentiate, or mature, to
become typical immune stimulatory
cells (Schuler and Steinman, 1985;
Inaba et al., 1986; Romani et al., 1989).
Although Langerhans cells were later
shown to have a separate cellular origin
from that of DCs (Merad et al., 2002),
they served as a model to understand
DC function. Ralph and his colleagues
discovered that maturing cells exhibited
different functional attributes during
different periods of time. The first function, antigen capture and presentation,
is exhibited by immature DCs. The
second function, accessory or costimulatory activity, is mediated by mature DCs. Although all DCs process
and present antigens, the maturation of
DCs determines the type and quality of
the immune response that will result
from recognition of DC-presented
antigens by T cells. There was also evidence that the environment in which
DCs mature exerts a major influence on
the form of adaptive immunity they promote. Thus, maturation of DCs serves as
the critical link between innate and adaptive T cell–dependent immunity.

of developing monocyte-derived DCs
had discovered that Flt-3L, a hematoin vitro (Trombetta et al., 2003). They
poietin that causes a dramatic 10–15-fold
proposed that this adaptation allows
expansion of DCs in mice and in
DCs to efficiently capture, process, and
humans, can be used to grow authentic
present antigens by preventing the
DCs in vitro. Once methods to genercomplete catabolism of protein antigens
ate large numbers of DCs became available, scientists could more easily study (Inaba et al., 2000). By allowing peptide–MHC II complexes to form inside
their immunizing properties. This dethe endocytic system, DCs optimized
velopment triggered a major expansion
their subsequent display at the cell
in research and greatly accelerated the
surface (Turley et al., 2000). The regupace of discovery.
Pursuing the concept that DCs are lation and composition of the endocytic system points to a hallmark
“nature’s adjuvant,” Ralph’s group
difference between DCs and macroincubated maturing DCs with anti
phages. Whereas macrophages are spegens in vitro and injected these cells
into mice and, eventually, humans. The cialized for continual antigen scavenging
DCs stimulated T cell
growth, and the expanded T cells recognized
the specific antigens presented on the MHC
products of the injected
DCs (Inaba et al., 1990).
These included microbial antigens in mice
(Inaba et al., 1993b) and
model antigens in humans
(Dhodapkar et al., 1999).
Prior to these discoveries, research on antigen
presentation had emphasized tissue culture systems and used previously
activated lymphocytes or
cloned lymphocyte lines.
With DCs, Ralph took
the problem into immunologically intact mice Ralph Steinman. Photo by Robert Reichert, The Rockefeller
and humans. By showing University, 1992.
that DCs initiated immunity specific for the
antigens they had captured, he justified and destruction, DCs process antigen in
a manner that generates the peptides
using these cells to develop immunothat bind to different types of antigentherapeutic strategies.
presenting molecules.
Endocytosis
Ralph’s studies with Michel on
Ralph had assumed that splenic and
endocytic receptors expressed by DCs
skin DCs were fully ready to initiate
introduced yet another field of study:
immunity because of their high content
how to increase the immunogenicity
of MHC II molecules. But when forof proteins by exploiting specific pathmer Cohn laboratory member Ira Mellways for antigen uptake. The research
man and colleagues at Yale brought
began with biomedical student William
their expertise in cellular molecular biSwiggard, who isolated DEC-205 (also
ology to the DC field, they found that
called CD205; Swiggard et al., 1995).
the MHC II proteins were mostly seWanping Jiang, a postdoctoral fellow in
questered within the endocytic system Michel’s laboratory, cloned the gene

and showed that it encoded an endocytic receptor, the first such receptor
identified on DCs in situ (Jiang et al.,
1995). By incorporating antigens into
monoclonal antibodies specific for DEC205 and administering these antibodies
to living animals, Daniel Hawiger, a student in Michel’s laboratory, first showed
that targeting antigens to DCs increased
the efficiency of presentation by 100fold (Hawiger et al., 2001). Although
the potency of DCs after antigen capture had been emphasized in the past,
Ralph and Michel’s work on antigen
handling revealed that this function of
DCs can be dramatically improved in
intact animals.
Beginning in 2000, in close collaboration with Michel and Hawiger, Ralph
uncovered roles for DCs in controlling
immune tolerance (Hawiger et al., 2001;
Steinman and Nussenzweig, 2002). To
analyze tolerance, Ralph took an approach first suggested by their discovery
that immature DCs induce antigenspecific tolerance in humans (Dhodapkar
et al., 2001). Ralph studied two forms
of antigen. One consisted of peptides
and proteins incorporated into antibodies that recognize DEC-205, which is
expressed on DCs in lymphoid tissues
(Hawiger et al., 2001). The other consisted of antigen within dying cells
(Iyoda et al., 2002; Liu et al., 2002).
When antigens were attached to anti–
DEC-205, and thus targeted directly to
immature DCs in vivo, in the absence
of inflammatory stimuli that promote
DC maturation, the antigens were processed and recognized by T cells but the
T cells were tolerized in response. In
contrast, delivery of a maturation stimulus together with the same targeted
antigen produced long-lived immunity
involving both helper and cytolytic
T cells (Hawiger et al., 2001; Liu
et al., 2005).
In addition to the classical pathway
of clonal deletion, the regulatory T cell,
particularly the variety programmed
by the protein Foxp3, is a powerful
mechanism of tolerance. In this issue of
the journal, a paper by a postdoctoral
fellow in Ralph’s laboratory (Sela et al.)
2340

DC-based vaccines

From the beginning, Ralph planned to
take DCs into medicine. His deep insights into the biology of DCs and his
interest in the control of immunity led
him to explore two novel approaches to
stimulate innate immunity.
One strategy was an active immunization against advanced cancer. Madhav
Dhodapkar, Ralph, and others developed ways to remove DCs from a patient, charge them with specific antigens,
and deliver them back into the patient
(Chang et al., 2005). This approach, resulting in expanded and sustained T cell
responses, recently approved by the US
Food and Drug Administration, is now
being used by many other laboratories.
The other vaccine strategy harnesses
the major features of DCs—location,
presentation, maturation, and formation of subsets—in situ. It involves engineering disease-relevant antigens into
monoclonal antibodies and targeting
them to particular DC-specific receptors. This approach, based on the work
of Hawiger et al. (2001), is currently
being applied to malaria, tuberculosis,
Leishmania, cancer, and AIDS. The resulting T cell–mediated immune response to targeted antigens, relative to
nontargeted antigens, is greater in efficacy, higher in magnitude, and associated with protection (Boscardin et al.,
2006; Trumpfheller et al., 2006, 2008;
Nchinda et al., 2008).
A critical and separate issue in targeting vaccine proteins is to incorporate a
stimulus or adjuvant to incite DC matura
tion. A paper in this issue, by Caskey et al.
of the Rockefeller Hospital, together
with Rafick Sékaly and his colleagues in
Port St. Lucie, shows that in healthy
humans the adjuvant double-stranded

RNA (poly ICLC) stimulated a broad
innate immune response mimicking that
induced by a live viral vaccine.
Ralph was that rare scientist who
lived through a period in which his endeavors came to fruition. He experienced a revolution in immunology and
both performed and witnessed work that
explained how DCs provide the physiological means to initiate clonal expansion, bring about tolerance, differentiate
lymphocytes into disease-fighting cells,
and develop memory, each in an antigen-specific manner. Ralph was excited
when he found novel cells in 1973, and
he died convinced that these cells had
become a novel force in medicine.
Carol L. Moberg (moberg@rockefeller.edu) is a
senior research associate in the Steinman
laboratory who has written extensively about
biomedical science. Her biography of René Dubos
was published by ASM Press in 2006 and her
history of the pioneering cell biology laboratories
at the Rockefeller University will be published by
the Rockefeller University Press in 2012.

Michel Nussenzweig, Svetlana Mojsov, and
Maggi Witmer-Pack made valuable contributions to this manuscript.
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